Off-Lable Pharmaceutical Marketing Attorney Tim McInnis

Off-Label Marketed For Nursing Home, Even Hospice, Patients According to Complaint Unsealed With Federal, State Whistleblower Settlements Totaling More Than $22.5 Million by Par Pharmaceuticals Illegal Sales Tactics for Megace ES Represented “Substantial Portion” of Drug’s Sales Over Three Years; One NJ Nursing Home Prescribed 6,900 Doses In Five Months to Patients All of Whom Were HIV-Free, According to Unsealed Complaint and Settlement Agreements Death, Deep Vein Thrombosis, and Toxic Reactions Leading to Impaired Kidney Function Were Side Effects in Elderly Yet Drug Manufacturer Created Separate Nursing Home Sales Force to Off-Label the Drug, According to NYC-Based National Qui Tam Whistleblowers’ Attorney Timothy J. McInnis, Esq. (NEWARK, NJ) –For at least four years, drug manufacturer Par Pharmaceutical Companies, Inc., and its subsidiary Par Pharmaceuticals, Inc. (together “Par”) risked the lives of senior citizens across the U.S., by illegally off-label marketing to the elderly Megace ES, a prescription approved only to help HIV and cancer patients gain weight by increasing their appetite, qui tam whistleblowers’ attorney Timothy J. McInnis announced.
After FDA approval of Megace ES in 2005, Par staffed a new highly aggressive outside sales force to push the drug for nursing home patients without HIV or cancer, even hospice patients, subjecting all to dangerous, even deadly side effects, according to documents unsealed with the drug manufacturer’s parent company’s $22.5 million plus interest settlement of federal and state False Claims Act violations.
Par’s civil settlement with the U.S. and Medicaid participating states followed the pharmaceutical corporation’s guilty plea in U.S. District Court to a misdemeanor information charging it with introducing into interstate commerce a misbranded drug, Megace® ES, in violation of the Federal Food, Drug and Cosmetic Act.The Woodcliff Lake, New Jersey-based drug manufacturer also paid a criminal fine.
More on this Off-Label Fraud example




Show Comments